BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28710075)

  • 1. The Cost-Effectiveness of Visual Triage of Human Papillomavirus-Positive Women in Three Low- and Middle-Income Countries.
    Campos NG; Jeronimo J; Tsu V; Castle PE; Mvundura M; Kim JJ
    Cancer Epidemiol Biomarkers Prev; 2017 Oct; 26(10):1500-1510. PubMed ID: 28710075
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
    Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
    BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
    Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
    Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.
    Mezei AK; Pedersen HN; Sy S; Regan C; Mitchell-Foster SM; Byamugisha J; Sekikubo M; Armstrong H; Rawat A; Singer J; Ogilvie GS; Kim JJ; Campos NG
    BMJ Open; 2018 Jun; 8(6):e020484. PubMed ID: 29895648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.
    Campos NG; Tsu V; Jeronimo J; Njama-Meya D; Mvundura M; Kim JJ
    Health Policy Plan; 2017 Sep; 32(7):956-968. PubMed ID: 28369405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
    Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
    Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
    BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
    Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
    BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea.
    Nguyen DTN; Simms KT; Keane A; Mola G; Bolnga JW; Kuk J; Toliman PJ; Badman SG; Saville M; Kaldor J; Vallely A; Canfell K
    BMJ Glob Health; 2022 Mar; 7(3):. PubMed ID: 35241461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
    Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
    JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study.
    Campos NG; Tsu V; Jeronimo J; Mvundura M; Kim JJ
    BMC Cancer; 2017 Nov; 17(1):791. PubMed ID: 29178896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
    Goldie SJ; Kim JJ; Wright TC
    Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
    Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study.
    Campos NG; Lince-Deroche N; Chibwesha CJ; Firnhaber C; Smith JS; Michelow P; Meyer-Rath G; Jamieson L; Jordaan S; Sharma M; Regan C; Sy S; Liu G; Tsu V; Jeronimo J; Kim JJ
    J Acquir Immune Defic Syndr; 2018 Oct; 79(2):195-205. PubMed ID: 29916959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
    Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
    J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.